



Clinical trial results:

OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

Summary

EudraCT number	2020-000864-42
Trial protocol	DE FR BE
Global end of trial date	04 June 2024

Results information

Result version number	v1 (current)
This version publication date	25 January 2025
First version publication date	25 January 2025

Trial information

Trial identification

Sponsor protocol code	IFX-1-P2.8
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04812535
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	InflaRx GmbH
Sponsor organisation address	Winzerlaer Strasse 2 , Jena, Germany, 07745
Public contact	Chief Medical Officer (CMO), InflaRx GmbH, +49 3641508 180, info@inflarx.de
Scientific contact	Chief Medical Officer (CMO), InflaRx GmbH, +49 3641508 180, info@inflarx.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 September 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 June 2024
Global end of trial reached?	Yes
Global end of trial date	04 June 2024
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Arm A:

- To assess the antitumor activity of IFX-1

Arm B:

- To determine the maximum tolerated dose (MTD) or recommended Phase II dose (RP2D)
- To assess the antitumor activity of IFX-1 + pembrolizumab
- To assess the safety profile of IFX-1 + pembrolizumab

Protection of trial subjects:

A steering committee was constituted to support the patient enrollment in both treatment arms and monitor patient safety throughout the study. The steering committee included the clinical study monitor and ≥ 3 cSCC experts (principal investigators included).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 March 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	Germany: 12
Country: Number of subjects enrolled	Spain: 5
Country: Number of subjects enrolled	United States: 4
Worldwide total number of subjects	30
EEA total number of subjects	26

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	6
From 65 to 84 years	16
85 years and over	8

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study sites in Belgium, France, Germany, Spain and United States of America. The first participant was screened on 31-Mar-2021. The last study visit occurred on 04-Jun-2024.

Pre-assignment

Screening details:

30 participants were screened.

Period 1

Period 1 title	Study period (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A

Arm description:

Vilobelimab monotherapy was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until end of treatment (EOT).

Arm type	Experimental
Investigational medicinal product name	Vilobelimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until EOT

Arm title	Arm B: Regimen 1:
------------------	-------------------

Arm description:

Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 400 mg on Days 1, 4, 8, and 15, followed by 800 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Investigational medicinal product name	Vilobelimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion

Routes of administration	Infusion
--------------------------	----------

Dosage and administration details:

administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 400 mg on Days 1, 4, 8, and 15, followed by 800 mg Q2W starting on Day 22 of Cycle 1 until EOT

Arm title	Arm B: Regimen 2:
------------------	-------------------

Arm description:

Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 600 mg on Days 1, 4, 8, and 15, followed by 1200 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Investigational medicinal product name	Vilobelimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 600 mg on Days 1, 4, 8, and 15, followed by 1200 mg Q2W starting on Day 22 of Cycle 1 until EOT

Arm title	Arm B: Regimen 3:
------------------	-------------------

Arm description:

Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Investigational medicinal product name	Vilobelimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until EOT

Number of subjects in period 1 ^[1]	Arm A	Arm B: Regimen 1:	Arm B: Regimen 2:
Started	10	3	6
Completed	1	1	1
Not completed	9	2	5
Consent withdrawn by subject	-	-	-
Death	7	2	4
Due to premature study termination by sponsor	2	-	1

Number of subjects in period 1 ^[1]	Arm B: Regimen 3:
Started	6
Completed	1
Not completed	5
Consent withdrawn by subject	1
Death	1
Due to premature study termination by sponsor	3

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 5 participants were enrolled but were screen failures and did therefore not receive the study drug.

Baseline characteristics

Reporting groups

Reporting group title	Arm A
-----------------------	-------

Reporting group description:

Vilobelimab monotherapy was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until end of treatment (EOT).

Reporting group title	Arm B: Regimen 1:
-----------------------	-------------------

Reporting group description:

Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 400 mg on Days 1, 4, 8, and 15, followed by 800 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Reporting group title	Arm B: Regimen 2:
-----------------------	-------------------

Reporting group description:

Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 600 mg on Days 1, 4, 8, and 15, followed by 1200 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Reporting group title	Arm B: Regimen 3:
-----------------------	-------------------

Reporting group description:

Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Reporting group values	Arm A	Arm B: Regimen 1:	Arm B: Regimen 2:
Number of subjects	10	3	6
Age categorical Units: Subjects			
Adults (18-65 years)	3	0	2
From 66-85 years	5	1	3
86 years and over	2	2	1
Age continuous Units: years			
arithmetic mean	74.0	81.3	72.8
standard deviation	± 13.4	± 13.3	± 10.6
Gender categorical Units: Subjects			
Female	5	1	2
Male	5	2	4

Reporting group values	Arm B: Regimen 3:	Total	
Number of subjects	6	25	
Age categorical Units: Subjects			
Adults (18-65 years)	2	7	
From 66-85 years	3	12	
86 years and over	1	6	

Age continuous Units: years arithmetic mean standard deviation	70.8 ± 9.6	-	
Gender categorical Units: Subjects			
Female	1	9	
Male	5	16	

Subject analysis sets

Subject analysis set title	FAS
Subject analysis set type	Full analysis

Subject analysis set description:

The Full Analysis Set (FAS) contains all patients assigned to study treatment.

Reporting group values	FAS		
Number of subjects	25		
Age categorical Units: Subjects			
Adults (18-65 years)	7		
From 66-85 years	12		
86 years and over	6		
Age continuous Units: years arithmetic mean standard deviation	73.8 ± 11.6		
Gender categorical Units: Subjects			
Female	9		
Male	16		

End points

End points reporting groups

Reporting group title	Arm A
Reporting group description: Vilobelimab monotherapy was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until end of treatment (EOT).	
Reporting group title	Arm B: Regimen 1:
Reporting group description: Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 400 mg on Days 1, 4, 8, and 15, followed by 800 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle	
Reporting group title	Arm B: Regimen 2:
Reporting group description: Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 600 mg on Days 1, 4, 8, and 15, followed by 1200 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle	
Reporting group title	Arm B: Regimen 3:
Reporting group description: Vilobelimab + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle	
Subject analysis set title	FAS
Subject analysis set type	Full analysis
Subject analysis set description: The Full Analysis Set (FAS) contains all patients assigned to study treatment.	

Primary: Frequency of dose-limiting toxicities (DLTs) by dose cohort

End point title	Frequency of dose-limiting toxicities (DLTs) by dose cohort ^[1]
End point description:	
End point type	Primary
End point timeframe: Cycle 1 Day 1 - Cycle 1 Day 36	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: DLTs were only analyzed descriptively.	

End point values	Arm A	Arm B: Regimen 1:	Arm B: Regimen 2:	Arm B: Regimen 3:
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	3	6	6
Units: participants				
Number of patients with DLT	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Best overall response rate

End point title	Best overall response rate ^[2]
-----------------	---

End point description:

Investigator assessed best overall response rate (best ORR) for Vilobelimab (Arm A) and Vilobelimab + pembrolizumab (Arms B), with response being defined as best response of complete response (CR)/confirmed CR (iCR) or PR/confirmed partial response (PR) (iPR) per modified RECIST v1.1/iRECIST

End point type	Primary
----------------	---------

End point timeframe:

Up to 36 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Best overall response rate was only analyzed descriptively.

End point values	Arm A	Arm B: Regimen 1:	Arm B: Regimen 2:	Arm B: Regimen 3:
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	3	6	6
Units: percent				
number (confidence interval 95%)				
Responder	10.0 (0.3 to 44.5)	0.0 (0.0 to 70.8)	16.7 (0.4 to 64.1)	33.3 (4.3 to 77.7)
CR/iCR	10.0 (0.3 to 44.5)	0.0 (0.0 to 70.8)	0.0 (0.0 to 45.9)	0.0 (0.0 to 45.9)
PR/iPR	0.0 (0.0 to 30.8)	0.0 (0.0 to 70.8)	16.7 (0.4 to 64.1)	33.3 (4.3 to 77.7)
Non-responder	90.0 (55.5 to 99.7)	100 (29.2 to 100.0)	66.7 (22.3 to 95.7)	66.7 (22.3 to 95.7)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 36 months

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.0
--------------------	------

Reporting groups

Reporting group title	Arm A
-----------------------	-------

Reporting group description:

Vilobelimab monotherapy was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until EOT.

Reporting group title	Arm B: Regimen 1:
-----------------------	-------------------

Reporting group description:

IFX-1 + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 400 mg on Days 1, 4, 8, and 15, followed by 800 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Reporting group title	Arm B: Regimen 2:
-----------------------	-------------------

Reporting group description:

IFX-1 + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 600 mg on Days 1, 4, 8, and 15, followed by 1200 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Reporting group title	Arm B: Regimen 3:
-----------------------	-------------------

Reporting group description:

IFX-1 + pembrolizumab combination therapy; Vilobelimab was administered as a 30-minute (-5/+10 minutes) intravenous infusion as follows: 800 mg on Days 1, 4, 8, and 15, followed by 1600 mg Q2W starting on Day 22 of Cycle 1 until EOT. Vilobelimab treatment was combined with pembrolizumab, administered as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 400 mg starting at Day 8 of Cycle 1 and then Q6W on Day 1 of each treatment cycle

Serious adverse events	Arm A	Arm B: Regimen 1:	Arm B: Regimen 2:
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 10 (70.00%)	2 / 3 (66.67%)	2 / 6 (33.33%)
number of deaths (all causes)	7	2	4
number of deaths resulting from adverse events	3	2	2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to meninges			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Tumour haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac-respiratory arrest			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nervous system disorders			
Haemorrhage intracranial			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
General physical health deterioration			

subjects affected / exposed	1 / 10 (10.00%)	2 / 3 (66.67%)	2 / 6 (33.33%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia of chronic disease			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Amyloidosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			

subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1

Serious adverse events	Arm B: Regimen 3:		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 6 (16.67%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events	1		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to meninges			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tumour haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac-respiratory arrest			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Haemorrhage intracranial			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Metabolic encephalopathy			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Presyncope			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaemia of chronic disease			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Amyloidosis			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COVID-19 pneumonia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia staphylococcal			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Arm A	Arm B: Regimen 1:	Arm B: Regimen 2:
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 10 (90.00%)	3 / 3 (100.00%)	5 / 6 (83.33%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			

subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Skin neoplasm bleeding subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Tumour haemorrhage subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Tumour ulceration subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Lymphoedema subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Lymphorrhoea subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Scalp haematoma subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Asthenia subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 3 (0.00%) 0	1 / 6 (16.67%) 2
Pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	2 / 6 (33.33%) 2
Chest pain			

subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Extravasation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
General physical health deterioration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Infusion site paraesthesia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Oedema peripheral			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Dry throat			
subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dyspnoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pulmonary hypertension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Depressed mood			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Panic attack subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Sleep disorder subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Investigations			
Weight decreased subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Intraocular pressure increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Lipase increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 3
SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Thyroxine free increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Injury, poisoning and procedural complications			

Fall			
subjects affected / exposed	2 / 10 (20.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Contusion			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Osteoradionecrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Traumatic haematoma			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Wound complication			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Wound haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Palpitations			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Nervous system disorders			
Dizziness			
subjects affected / exposed	2 / 10 (20.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	1
Dementia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Neuropathy peripheral			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Anaemia of chronic disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Eosinophilia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Vitreous floaters			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dental discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Gastritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral hyperkeratosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral pain			

subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Hyperhidrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Actinic keratosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin discharge			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Pollakiuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Back pain			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Trismus subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cellulitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Gingivitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Tooth abscess subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Wound infection pseudomonas subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Metabolism and nutrition disorders			
Hyponatraemia			

subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Dehydration			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypomagnesaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Arm B: Regimen 3:		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 6 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Skin neoplasm bleeding			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Tumour haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Tumour ulceration			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Vascular disorders			

Hypertension			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Lymphoedema			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Lymphorrhoea			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Scalp haematoma			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Chest pain			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Extravasation			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
General physical health deterioration			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Infusion site paraesthesia			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Dry throat			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Pulmonary hypertension			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Depressed mood			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Panic attack			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Sleep disorder			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Investigations			

Weight decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Intraocular pressure increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Lipase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Thyroxine free increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Contusion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Osteoradionecrosis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Traumatic haematoma subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Wound complication			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Wound haemorrhage subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Cardiac disorders Cardiac failure subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Palpitations subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Dementia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Headache subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Anaemia of chronic disease subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Eosinophilia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Eye disorders			

Vitreous floaters subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Constipation subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Dental discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Dry mouth subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Gastritis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Oral hyperkeratosis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Oral pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Vomiting subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Skin and subcutaneous tissue disorders			
Hyperhidrosis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Actinic keratosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Erythema			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pruritus</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Rash maculo-papular</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Skin discharge</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 6 (16.67%)</p> <p>1</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>1 / 6 (16.67%)</p> <p>1</p> <p>0 / 6 (0.00%)</p> <p>0</p>		
<p>Renal and urinary disorders</p> <p>Chronic kidney disease</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pollakiuria</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 6 (0.00%)</p> <p>0</p> <p>1 / 6 (16.67%)</p> <p>1</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Back pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Myalgia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Trismus</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p>		
<p>Infections and infestations</p> <p>Nasopharyngitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Urinary tract infection</p>	<p>0 / 6 (0.00%)</p> <p>0</p>		

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Gingivitis			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Oral candidiasis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Tooth abscess			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Wound infection pseudomonas			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	2		
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Decreased appetite			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dehydration			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Hypomagnesaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
---	--------------------	--	--

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 December 2020	This is the clinical study protocol version 2.2, which is the first version patients were enrolled with.
12 May 2021	This is the clinical study protocol version 4.0, which is the second and last version, patients were enrolled with.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was prematurely terminated due to a strategic decision by the sponsor. Therefore, the total number of participants enrolled is smaller than planned (actually enrolled and treated: 25, planned: 70).

Notes: